A double-blind, double-dummy, randomized, parallel groups study to assess the efficacy, safety and tolerability of switching patients with early Parkinson's disease (PD) from pramipexole IR [immediate release] to pramipexole ER [extended release] or pramipexole IR.

Trial Profile

A double-blind, double-dummy, randomized, parallel groups study to assess the efficacy, safety and tolerability of switching patients with early Parkinson's disease (PD) from pramipexole IR [immediate release] to pramipexole ER [extended release] or pramipexole IR.

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Apr 2014

At a glance

  • Drugs Pramipexole (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 22 Feb 2010 FDA has approved once-daily MIRAPEX ER for the treatment of early parkinson's disease, according to a Boehringer Ingelheim media release. The FDA approval was supported by this trial.
    • 16 Sep 2009 Results have been presented at EFNS 2009.
    • 07 Jun 2009 Results were presented at the 13th International Congress of Parkinson's Disease and Movement Disorders.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top